Comparing antiplatelet therapies in patients with low platelet counts
Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia
This study is testing which antiplatelet medication, clopidogrel or ticagrelor, works better for people with low platelet counts who are having heart procedures to see which one helps prevent complications like bleeding or heart attacks.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Methodist Health System Academic / other |
| Locations | 1 site (Dallas, Texas) |
| Trial ID | NCT06223607 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of dual antiplatelet therapy (DAPT) using clopidogrel versus ticagrelor in patients with chronic thrombocytopenia undergoing percutaneous coronary intervention (PCI). It aims to determine which medication better balances the risks of bleeding and ischemic events following the procedure. The study will analyze data from patients who received PCI with either drug-eluting stents or bare metal stents between April 2018 and July 2021, focusing on their platelet counts and outcomes post-intervention.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a history of thrombocytopenia and who have undergone PCI with either drug-eluting or bare metal stents.
Not a fit: Patients who have died within 48 hours post-PCI or who received DAPT prior to cardiac catheterization may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for patients with thrombocytopenia undergoing PCI, potentially reducing bleeding complications.
How similar studies have performed: While there is limited data specifically addressing this patient population, studies on antiplatelet therapy in broader populations have shown varying outcomes, indicating that this approach may provide new insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥ 18 years * PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021) * Thrombocytopenia defined as platelet count \<100 x103 /µL on at least one occasion prior to PCI * At least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor Exclusion Criteria: * Death within 48 hours post-PCI * DAPT prior to cardiac catheterization
Where this trial is running
Dallas, Texas
- Methodist Dallas Medical Center — Dallas, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Jessica Rago Crotty, Pharm D — Methodist Midlothian Medical Center
- Study coordinator: Bethany Brauer
- Email: mhsirb@mhd.com
- Phone: 214-947-4681
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.